bluebird bio Announces Pricing of Public Offering of Common Stock
May 18 2020 - 9:32PM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) today announced the pricing of
an underwritten public offering of 9,090,910 shares of its common
stock at a public offering price of $55.00 per share, before
underwriting discounts. In addition, bluebird bio has granted the
underwriters a 30-day option to purchase up to an additional
1,363,636 shares of common stock. All of the shares in the offering
are to be sold by bluebird bio.
Goldman Sachs & Co. LLC, BofA Securities and Cowen are
acting as joint book-running managers of the offering. The offering
is expected to close on or about May 21, 2020, subject to customary
closing conditions.
bluebird bio anticipates the total gross proceeds from the
offering (before deducting underwriters’ discounts and commissions
and estimated offering expenses) will be approximately $500
million, excluding any exercise of the underwriters’ option to
purchase additional shares.
The shares are being offered by bluebird bio pursuant to an
automatically effective shelf registration statement that was
previously filed with the Securities and Exchange Commission (SEC).
A preliminary prospectus supplement relating to and describing the
terms of the offering was filed with the SEC on May 18, 2020. The
final prospectus supplement relating to the offering will be filed
with the SEC and will be available on the SEC’s website at
www.sec.gov. When available, copies of the final prospectus
supplement and the accompanying prospectus relating to these
securities may also be obtained by contacting one of the following:
Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West
Street, New York, NY 10282, telephone: (866) 471-2526, facsimile:
(212) 902-9316, email: prospectus-ny@ny.email.gs.com; BofA
Securities, NC1-004-03-43, 200 North College Street, 3rd floor,
Charlotte, NC 28255-0001, Attn: Prospectus Department, or via
email: dg.prospectus_requests@bofa.com; and Cowen and Company, LLC,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York 11717, Attn: Prospectus Department, by telephone
at (833) 297-2926, or by email at
PostSaleManualRequests@broadridge.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or
jurisdiction.
About bluebird bio, Inc.
bluebird bio is pioneering gene therapy with purpose. From our
Cambridge, Mass., headquarters, we’re developing gene therapies for
severe genetic diseases and cancer, with the goal that people
facing potentially fatal conditions with limited treatment options
can live their lives fully. Beyond our labs, we’re working to
positively disrupt the healthcare system to create access,
transparency and education so that gene therapy can become
available to all those who can benefit.
bluebird bio is a human company powered by human stories. We’re
putting our care and expertise to work across a spectrum of
disorders including cerebral adrenoleukodystrophy, sickle cell
disease, β-thalassemia and multiple myeloma, using three gene
therapy technologies: gene addition, cell therapy and
(megaTAL-enabled) gene editing.
bluebird bio has additional nests in Seattle, Wash.; Durham,
N.C.; and Zug, Switzerland.
bluebird bio is a trademark of bluebird bio, Inc.
Forward-Looking Statements
This release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements regarding the anticipated final terms, timing
and completion of the proposed offering. Any forward-looking
statements are based on management’s current expectations of future
events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements.
These risks and uncertainties include, but are not limited to,
risks and uncertainties related to market conditions and
satisfaction of customary closing conditions related to the
proposed public offering; the risks that the COVID-19 pandemic and
resulting economic conditions will have a greater impact on the
company’s operations and plans than anticipated, and that the
company will not be able to realize the savings under the revised
operating plan or successfully execute the revised operating plan;
that our amended collaboration with BMS will not continue or be
successful; that preliminary positive efficacy and safety results
from our prior and ongoing clinical trials will not continue or be
repeated in our ongoing or future clinical trials; the risk of
cessation or delay of any of the ongoing or planned clinical
studies and/or our development of our product candidates, including
due to delays from the COVID-19 pandemic’s impact on healthcare
systems; the risk that the current or planned clinical trials of
our product candidates will be insufficient to support regulatory
submissions or marketing approval in the United States and European
Union; the risk that regulatory authorities will require additional
information regarding our product candidates, resulting in delay to
our anticipated timelines for regulatory submissions, including our
applications for marketing approval; the risk that the FDA will
reject the BLA resubmission for ide-cel, resulting in delay to our
anticipated timeline for marketing approval; the risk that we will
encounter challenges in the commercial launch of ZYNTEGLO in the
European Union, including in managing our complex supply chain for
the delivery of drug product, in the adoption of value-based
payment models, or in obtaining sufficient coverage or
reimbursement for our products; and the risk that any one or more
of our product candidates will not be successfully developed,
approved or commercialized. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled “Risk Factors”
in our annual report on Form 10-K and our most recent quarterly
report on Form 10-Q, as well as discussions of potential risks,
uncertainties, and other important factors in our subsequent
filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and bluebird bio undertakes no duty to update this information
unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200518005782/en/
Investors & Media
Investors: Ingrid Goldberg, 410-960-5022
Ingrid.goldberg@bluebirdbio.com OR Elizabeth Pingpank, 617-914-8736
epingpank@bluebirdbio.com
Media: Jenn Snyder, 617-448-0281 jsnyder@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024